ARCHIVES

Two Phase III Ramucirumab Trials Both Deliver Improved Overall and Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

NIH Will Target Genomics, Translational Research, And Training, Collins Tells Congress

April 30, 2010

Drug Approvals: FDA Grants Accelerated Approval to Imbruvica

November 15, 2013

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

December 27, 2013

UPCI To Lead Clinical Trials Of Eli Lilly’s Oncology Agents.

July 6, 2001

FDA Staff Failed To Explain Approval Standards, Correct Misconceptions.

April 13, 2007

In Brief: NCI Authorization Should be $1.3 Billion, Humphrey Tells Kennedy; GOG Gets New Life

March 3, 1978